340 related articles for article (PubMed ID: 27925175)
1. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.
Campos NG; Tsu V; Jeronimo J; Njama-Meya D; Mvundura M; Kim JJ
Health Policy Plan; 2017 Sep; 32(7):956-968. PubMed ID: 28369405
[TBL] [Abstract][Full Text] [Related]
3. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
Campos NG; Castle PE; Wright TC; Kim JJ
Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon.
Sharma M; Seoud M; Kim JJ
Vaccine; 2017 Jan; 35(4):564-569. PubMed ID: 28017434
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
Kim JJ; Wright TC; Goldie SJ
J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
[TBL] [Abstract][Full Text] [Related]
6. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
[TBL] [Abstract][Full Text] [Related]
7. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
[TBL] [Abstract][Full Text] [Related]
8. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.
Shi JF; Canfell K; Lew JB; Zhao FH; Legood R; Ning Y; Simonella L; Ma L; Kang YJ; Zhang YZ; Smith MA; Chen JF; Feng XX; Qiao YL
BMC Cancer; 2011 Jun; 11():239. PubMed ID: 21668946
[TBL] [Abstract][Full Text] [Related]
10. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
Diaz M; Kim JJ; Albero G; de Sanjosé S; Clifford G; Bosch FX; Goldie SJ
Br J Cancer; 2008 Jul; 99(2):230-8. PubMed ID: 18612311
[TBL] [Abstract][Full Text] [Related]
11. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial.
Mezei AK; Pedersen HN; Sy S; Regan C; Mitchell-Foster SM; Byamugisha J; Sekikubo M; Armstrong H; Rawat A; Singer J; Ogilvie GS; Kim JJ; Campos NG
BMJ Open; 2018 Jun; 8(6):e020484. PubMed ID: 29895648
[TBL] [Abstract][Full Text] [Related]
12. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
14. Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Kim JJ
BMC Cancer; 2017 Nov; 17(1):791. PubMed ID: 29178896
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
Sharma M; Ortendahl J; van der Ham E; Sy S; Kim JJ
BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
17. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
Goldie SJ; Kuhn L; Denny L; Pollack A; Wright TC
JAMA; 2001 Jun; 285(24):3107-15. PubMed ID: 11427139
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
[TBL] [Abstract][Full Text] [Related]
19. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
[TBL] [Abstract][Full Text] [Related]
20. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
